Make an Investment

Opportunities for purchasing stock in VG Life Sciences exist currently through traditional and discount brokerages, such as Charles Schwab, Scottrade, E*TRADE, TD Ameritrade, Fidelity, Merrill Edge, ShareBuilder, and more. Additional opportunities exist for institutional and accredited investors to support key phases of VG Life Sciences’ TPT and MDT pre-clinical and clinical trials.

Institutional and accredited investors interested in these opportunities should email investors@vglifesciences.com with a subject line of “Accredited Investor” for additional information.

For shareholder convenience, we have included a current quote, information regarding restricted stock, and links to SEC filings and discourses.


Quote

  • Stock VGLS $0.0071+0.0000 +0.0000%
Chart of VGLS

Restricted Stock

Shareholders who hold physical certificates and want to have the restrictive legend removed and deposit their shares into a brokerage account can find information how to do so here. To deposit shares into a brokerage account, the shares must generally be free-trading and have no restrictions placed on them.

Please open and read the links below for additional step-by-step instructions. Once the restriction is removed, your broker will arrange for the shares to be deposited to your brokerage account.

“VGLS advancements are inspiring to the surrounding BioTech world, we look forward to supporting them in their future of discovery for an optimistic health outcome.”

Contact

VG LIFE SCIENCES CORPORATE COUNSEL
Robert A. Forrester, Esq.
1215 Executive Drive West, Suite 102
Richardson, TX 75081
Tel: 972-437-9898
Fax: 972-480-8406
Email: raforrester@sbcglobal.net

VG LIFE SCIENCES INC. STOCK TRANSFER AGENT
Registrar and Transfer Co.
10 Commerce Dr.
Cranford, NJ 07016-1010
Tel: 1-800-866-1340
Attention: Ana Gois, Account Manager
For more information, please email investor@vglifesciences.com


Shareholder Letters


SEC Filings & Disclosures

On June 20, 2014, the company filed a Form 10-12G with the Securities and Exchange Commission and, as of August 19, 2014, is required to make ongoing disclosures and reports under the SEC’s online EDGAR system including annual and quarterly reports on Form 10-QSB or Form 10-KSB, as well as Current Reports on Form 8-K. The company responded to SEC comments on September 10, 2014 and October 1, 2014. The company cleared SEC comments on October 14, 2014.

Previously, on March 25, 2009, the company filed a Form 15 with the Securities and Exchange Commission terminating its reporting obligations under Section 12(g) of the Securities Exchange Act of 1934. As a result, the company was no longer eligible or required to make ongoing disclosures and reports under the SEC’s online EDGAR system including annual and quarterly reports on Form 10-QSB or Form 10-KSB, as well as Current Reports on Form 8-K. The company addressed this gap in disclosure by making disclosures under the OTCIQ service.

SEC filings on EDGAR are available; however, investors should also consult the company’s disclosures made on the OTCIQ system (see below) and the company’s standard press releases.


Stock Information (As of September 26, 2014)

STOCK SHARES
Issued and Outstanding Common Shares 30,320,628
Authorized Common Shares 150,000,000
Issued and Outstanding Preferred Shares 9,715,443
Authorized Preferred Shares 20,000,000